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LONGITUDINAL ASSESSMENT OF BLOOD BRAIN BARRIER DISRUPTION IN
PRIMARY HIV INFECTION. Elham Rahimy, Fang-Yong Li, Lars Hagberg, Dietmar
Fuchs, Kevin Robertson, Dieter J. Meyerhoff, Henrik Zetterberg, Richard W. Price,
Magnus Gisslén, and Serena Spudich. Department of Neurology, Yale University, New
Haven, CT, USA.
Abnormal blood brain barrier (BBB) permeability has been implicated in the
neuropathogenesis of chronic HIV infection. As neurocognitive impairment can persist
despite effective combination antiretroviral therapy (cART), it is possible that irreversible
central nervous system (CNS) processes are initiated in early infection, before cART is
typically initiated. We analyzed the natural history of BBB permeability in primary HIV
infection (PHI), and the effects of cART initiated during this period. CSF:Serum albumin
quotient (QAlb), a marker of BBB permeability, was measured in longitudinal
observational studies of PHI. We analyzed trajectories of QAlb pre- and post-cART using
mixed-effects models, and associations between QAlb and CSF neurofilament light chain
(NFL), N-acetylaspartate:creatinine (NAA:Cr, a magnetic resonance spectroscopy
biomarker for neuronal integrity), and neuropsychological testing. Age-adjusted QAlb was
elevated in PHI vs. controls at baseline (n=106, median 91 days post infection, dpi; n=64;
p=0.02). Before cART, QAlb increased over time in 84 participants with normal baseline
QAlb (p=0.006), and decreased in 22 with high baseline QAlb (p=0.011). QAlb correlated at
baseline and longitudinally with NFL (r=0.497, p<0.001; r=0.555, p<0.001) and NAA:Cr
in parietal grey matter (r=-0.352, p=0.015, r=-0.387, p=0.008), but not
neuropsychological performance. QAlb did not change after a median 398 days of cART
initiated at 225 dpi (p=0.174). QAlb rises during early HIV, associates with neuronal
injury, and does not significantly improve over a year of treatment. HIV BBB-associated
neuropathogenesis may be initiated in early infection.
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INTRODUCTION
As of 2016, the CDC reports more than 1.2 million individuals are living with human
immunodeficiency virus (HIV) in the United States, with as many as 1 in 8 unaware of
their diagnosis1,2. HIV has significant genetic diversity, exhibiting different strains,
subtypes, and even sub-subtypes, internationally. HIV-1 is the most predominant form
worldwide, apart from western Africa3, and will be the focus of this thesis. Herein, 'HIV'
refers to HIV-1.

Neurocognitive dysfunction in HIV
I. HIV-associated neurocognitive disorder (HAND)
HIV infection can have significant systemic ramifications, and the central nervous system
(CNS) is no exception. Chronic exposure to HIV can frequently lead to devastating
neurological complications, with approximately one third of untreated patients
developing HIV associated dementia (HAD) 4. HAD is characterized by severe cognitive,
motor, and behavioral disturbances associated with global cerebral atrophy, with
subcortical areas exhibiting particular susceptibility 5. Given the morbidity of the illness
in the absence of treatment, HAD is considered an AIDS-defining illness, with disease
severity correlating with the degree of CD4+ suppression6,7. With the introduction of
highly active antiretroviral therapy (HAART)/combination antiretroviral therapy (cART)
in 1995, and thus restoration of CD4+ counts and effective viral load suppression, the
incidence of HAD has significantly decreased to as low as 5%8,9. However, a milder
spectrum of neurocognitive deficits persists despite successful cART treatment, effecting
up to 50% of chronically infected patients8-10. HIV-associated neurocognitive disorders
(HAND) is an umbrella term for this observed spectrum of neurocognitive complications,
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comprised of three categories: asymptomatic neurocognitive impairment (ANI), mild
neurocognitive disorder (MND), and HAD, in increasing severity4,11.
As indicated above, HAND predominantly involves the subcortical region and
frontostriatal circuits, often manifesting as cortical atrophy and white matter signal
hyperintensities detectable on magnetic resonance imaging (MRI)12, although these
findings are neither specific nor sensitive13,14. Corresponding to the imaging findings, the
cognitive domains most commonly affected include motor, psychological (agitation,
apathy, depression), executive, speed of processing information, and attention, with very
limited involvement of language, judgment, and reasoning12,15. Like any form of
dementia, HAND is a clinical diagnosis, and the above domains may be assessed
clinically with a battery of neuropsychological testing (ie, trail making, grooved
pegboard), which allows for classification in one of the HAND categories. All categories
of HAND require impairment in at least 2 tested domains, while the degree of
impairment in functional performance determines the category: no impairment qualifies
as ANI, mild impairment qualifies as MND, and moderate-to-severe impairment qualifies
as HAD16. Undoubtedly, these neurocognitive deficits, even when mild, can have a
severe impact on the patient's quality of life, and may even compromise cART adherence,
resulting in viral resistance and disease progression17. Thus, the continued foothold of
HAND in post-cART era is an issue necessitating better understanding and further
investigation.

II. Neuropathogenesis in HAND
Since the mid-1980s, numerous autopsy studies have characterized the histological
hallmarks of HAD with relative consensus: If HAD is the clinical manifestation of severe
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neurocognitive deficits, HIV-encephalitis (HIVE) is the pathologic correlate. Apart from
gross evidence of diffuse brain atrophy--indicative of neuronal loss--and correspondingly
enlarged ventricles, tissue specimens in classic HAD demonstrate wide-spread
inflammation. This characteristic inflammation, termed HIVE, is defined by the presence
of activated resident macrophages (ie, microglia) and infiltrating peripheral macrophages,
with specific findings as follows: multinucleated giant cells expressing viral antigens like
p24 (likely representing viral fusion of macrophages), activated microglial nodules,
perivascular 'cuffs' (leukocyte aggregation in the perivascular space), marked astrocytosis
(astrocyte activation and dysfunction)18, white matter gliosis and demyelination, synaptodendritic injury, and the presence of detectable virus production19-23.
Even in the post-cART era, post-mortem analysis of patients with mild forms of
HAND surprisingly still shows marked neuroinflammation24. Although pathologically
similar to HIVE, productive HIV infection is not detectable, and the structural sites of
inflammation are different, now primarily involving the hippocampus and surrounding
peri-entorhinal cortex with less involvement of the basal ganglia6. While some argue that
the milder forms of HAND in the post-cART era may represent a different pathological
process from pre-cART HAD, it is clear that neuroinflammation likely contributes to
pathogenesis in both. In fact, the degree of histologic neuroinflammation correlates
strongly with clinical progression of HAND6; in 1995, Glass et al showed a strong
correlation between neurologic disease progression and macrophage staining, whereas
HIV-1 staining (ie, gp41 expression) demonstrated a weak correlation at best25. These
findings by Glass, and similar pathologic and experimental findings by other researchers
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in years to come, implicated inflammation as a key player in HIV-mediated
neurodegeneration, more so than viral load.
Neuronal toxicity is thought to be primarily due to indirect mechanisms, such as
inflammation, as repeated histological and in vitro studies have shown HIV to have very
limited, if any, infection of neurons. Few post-mortem PCR studies have shown that HIV
has the capability to invade neurons26,27, although the infected proportion is small (as
neurons do not express required HIV receptors) and the infection is likely nonproductive
(as neurons cannot regenerate)28. Although this putative neuronal infection is thought to
have an inconsequential role in neuropathogenesis, replication-derived viral proteins can
exert neurotoxic effects either directly via apoptotic activation or indirectly via induction
of inflammatory cytokines: Tat (transcriptional transactivator), gp120 (envelope
glycoprotein), and VPR (viral protein R) have been most strongly implicated in HIVmediated neurodegeneration, stimulating apoptosis through activation of caspase-3 or -8,
and up-regulating microglial synthesis of IL-1β and TNF-α6,19,20,28,29. Thus, HIV is
thought to cause neuronal injury via induction of a pro-inflammatory state, but also via
secretion of neurotoxic viral proteins, with a strong interplay and synergistic effect
between these two mechanisms. Notably, excito-toxicity is thought to be the common
endpoint of both pathways, as inflammatory cytokines and HIV-encoded proteins have
been shown to increase extracellular glutamate concentration in the CNS, resulting in
excess activation of the N-methyl-d-aspartate (NMDA) receptor, and subsequent
apoptosis20,30,31. (For a discussion on how HIV breaches the BBB and induces
neuroinflammation, see section titled "Role of the blood brain barrier" below.)
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III. Theories underlying persistence of HAND despite successful cART
As indicated in the above sections, even in the context of successful cART therapy (ie,
undetectable viral load on ultrasensitive tests), HAND persists in milder forms. Several
explanations have been offered, although the answer is still unclear. A few theories will
be discussed briefly below.
One possibility is the presence of continued low-grade neuroinflammation even
with complete viral suppression, as suggested by the autopsy studies of Tavazzi et al
demonstrating marked neuroinflammation without histologic signs of viral replication
(referenced above in "Neuropathogenesis of HAND"). It is speculated that resolution of
inflammation in the CNS is slower than the periphery32, and may remain unchecked for
years, with persistently abnormal inflammatory biomarkers9.
A second possibility is continued low-grade viral replication in the CNS. As an
immune privileged site, the brain may serve as a perfect viral sanctuary for HIV to escape
exposure to cART circulating in the periphery33. cART penetration into the CNS is
limited, even in regimens with a high 'CNS Penetration Effectiveness' (see "cART therapy
overview" below), thus allowing for continued CNS replication even with viral
eradication in the periphery9. Persistence of HIV in the CNS may also allow for evolution
of drug-resistant strains, as the presence of genetically distinct populations in the CSF
versus the plasma has been well documented in chronic infection19,34.
A third possibility is the confounding effect of comorbidities prevalent in HIV+
patients35; although the resulting neurocognitive diseases are histologically distinct from
HAND, they may be difficult to distinguish clinically. Such confounders include medical
comorbidities (ie, cardiovascular disease, co-infection with hepatitis)36-41, psychological
disease (ie, depression)42-44, drug abuse (ie, crack/cocaine)41,45, medication-related side
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effects, and increased susceptibility to age-related neurodegenerative processes (ie,
acceleration of amyloid-driven diseases such as Alzheimer's and Parkinson's)6,46-51. In
regards to medication-related side effects, ART therapy is known to cause neurotoxicity,
the severity of which may correlate with CNS Penetration Effectiveness6,44,52.
Perhaps most relevant to the purpose of this thesis, the fourth possibility is that
this persisting neurocognitive impairment may represent irreversible neuronal damage
accrued prior to the initiation of cART, even in early infection53. Thus, investigative
efforts have been drawn towards elucidating and characterizing the earliest stages of HIV
neuroinvasion and associated neuronal injury, as will be explored further below.

Initiation of neuropathogenesis in early HIV infection
Primary HIV infection (PHI) refers to the earliest stage of systemic infection, from time
of transmission up to 12 months post-transmission, encompassing the time of
seroconversion and establishment of virus load set point54. An acute retroviral syndrome
(ARS) develops in over half of PHI patients, and is thought to represent either a direct
cytotoxic effect or immunologic response to the high load viremia typical of the acute
phase of infection. Clinical symptoms of ARS tend to be nonspecific, classically a
mononucleosis- or influenza-like syndrome which can last several days to weeks;
however, neurological symptoms, such as aseptic meningitis, encephalitis, or
radiculopathy, develop in up to 17% during seroconversion, and may be associated with a
more rapid progression of neurocognitive deficits55,56. Several studies have demonstrated
HIV infiltration of the CNS during PHI57-59, as indicated by the presence of HIV RNA in
the CSF compartment, as early as eight days post-infection, even preceding the
manifestation of neurological symptoms 4,59-62. CNS immune activation accompanies this
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viral invasion as reflected by elevations of CSF white blood count, the soluble CSF
biomarkers neopterin (reflecting macrophage activation) and CXCL-10/IP-10 (a
lymphocyte chemokine), and T lymphocyte activation in CSF4,63-66. Furthermore, markers
of immune activation may reflect degree of viral load and neurocognitive impairment67.
Accumulating evidence suggests that this pro-inflammatory state coincides with
neuronal damage during PHI. Neurofilament light chain (NFL) is one of three subunits
which comprises the cytoskeletal protein neurofilament, an intermediate filament
essential for axonal support of myelinated neurons. It is an established CSF biomarker of
axonal damage in a variety of neurological processes, with growing prominence in HIVrelated neurodegeneration. The reason for this trend is that, unlike other CSF biomarkers
which are reflective of viral load or immune activation, NFL directly reflects the severity
of active neuronal damage32. Elevations in NFL have also been demonstrated in PHI,
even in neuroasymptomatic patients, indicative of subclinical injury50,68.
Another useful method of detecting neuronal damage and CNS inflammation
utilizes magnetic resonance spectroscopy (MRS), a noninvasive quantitative MR
technique which measures alterations in cerebral metabolite levels. Previous MRS studies
have shown elevation of inflammatory cerebral metabolites in acute HIV (prior to
antibody seroconversion) which increases longitudinally over time in PHI prior to
cART4,69,70, as well as elevation in neuronal injury metabolites responsive to ART 69. The
cerebral metabolite N-acetylaspartate (NAA) is a marker of neuronal viability and
number, and is often expressed as a value normalized to creatinine (NAA:Cr). We have
previously shown a strong correlation between high NFL and low NAA:Cr in the parietal
grey matter of neurosymptomatic PHI subjects 68. Thus, crucial processes during the
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primary phase of viral infection may underlie the initiation of HIV associated CNS
injury.
Whether clinically overt signs of neurocognitive impairment begin in PHI is not
clear, as studies have been limited. A meta-analysis has previously concluded that
cognitive deficits in early HIV infection are rare and mild15, although several primary
studies have been published since then, either noting deficits in a large subgroup71,72, or
finding no deficits73,74. Notably, these studies varied in the timing of their analysis
relative to date of transmission, a relevant point if the earlier phases of infection are
dominated by sub-clinical neuronal injury.

Role of the blood brain barrier
I. Anatomy of the blood brain barrier
The highly restrictive blood brain barrier (BBB) defines almost the entirety of the brain's
capillary endothelium, bestowing the CNS with a specialized microenvironment distinct
from systemic circulation75. These endothelial cells are tightly opposed via junctional
protein complexes, called zonulae occludentes, which prevents any paracellular
passage76. Other components of the neurovascular unit (NVU) include peri-endothelial
cells, specifically pericytes and astrocytes; the NVU also interacts with the resident CNS
immune cells, called microglia77,78(Figure 1). The ratio of albumin in the cerebrospinal
fluid to albumin in the serum (CSF:serum albumin concentration quotient, or QAlb) is a
specific marker for BBB permeability79. Albumin is synthesized exclusively in the liver
and is largely excluded from the CSF. Upon deregulation of the neurovascular unit and
sequential loss of tight junctions, BBB permeability to albumin increases, resulting in an
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increased QAlb. Some researchers caution against using QAlb as a blood-brain barrier
marker and state that it actually reflects the permeability of the blood-CSF barrier at the
choroid plexus80, since the choroid vasculature is more prone to inflammation and
'leakiness' compared to the intraparenchymal vasculature. But in cases of stroke, which
leaves the choroid plexus intact and injures the cerebrovascular endothelial cells, QAlb is
increased81, suggesting that QAlb is a marker of both barriers.

Figure 1. Key players of the blood brain barrier are shown. Endothelial cells are conjoined by tight
junctional proteins, the expression of which are affected by ligand-receptor interactions. Pericytes closely
encircle the endothelial cells within the basal lamina, while astrocyte endfeet provide support just outside
of the basal lamina. The resident central nervous system macrophages, microglia, interact with the
neurovascular unit within the perivascular space. Adapted with permission from Abbott NJ et al. (2006)
Astrocyte–endothelial interactions at the blood–brain barrier, Nature Reviews Neuroscience. 7: 41–53.

Expression of the endothelial junctional proteins, such as occludin-1 and ZO-1,
and the viability of endothelial cells are highly influenced by environmental factors,
including expression of pro-inflammatory cytokines such as TNF-α and IL-1β 48,82,83,
direct infection by various neurotropic viruses39,84, or exposure to cytotoxic molecules in

10
the serum85. All three of these factors are thought to be involved in the pathogenesis of
HAND (See "Neuropathogenesis in HAND" above). Is it possible that the BBB, the
guardian of the CNS so susceptible to environmental factors, is implicated in the neuropathogenesis of HAND?

II. Dysregulation of the blood brain barrier in HIV
In order to exert its neurological effects, HIV and/or its viral products must first traverse
the BBB. Although the mechanisms have not yet been fully clarified, several models
have been proposed. The aptly named "Trojan horse theory" is perhaps the most widely
accepted, suggesting the HIV virus crosses the BBB primarily via infection of peripheral
monocytes destined to take up residence in the CNS as macrophages 20. Although this
model indicates that HIV is able to traverse the largely intact BBB, increased
permeability of the BBB has been strongly implicated in the progression of HIV
neurological dysfunction68,86-89. Since the early 1990s, studies have shown that QAlb is
increased in infected individuals90,91 and is strongly associated with the presence of
neurological signs/symptoms92. Around this time, post-mortem studies of chronically
infected AIDS patients provided tissue evidence of the correlation between BBB
dysregulation and neurological impairment, as serum protein deposition in subcortical
white matter was greater in those with neurological symptoms89. Peluso and colleagues
reported a significant correlation between the axonal injury marker NFL and QAlb, further
suggesting a possible relationship between a dysregulated BBB and neurological
dysfunction68. In line with this observation, several studies have shown that the neuronal
injury accrued upon CNS infiltration is not a direct result of cytolytic infection61,88. On
the contrary, within the CNS, HIV infection is restricted to macrophages, microglia, and,
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to a lesser extent, endothelial and peri-endothelial cells of the neurovascular unit (ie,
astrocytes and pericytes) which compromise the BBB85,93. As will be discussed below, it
is the downstream effects of HIV infection in these cells that will culminate in neuronal
injury through a compromised BBB.
It is speculated that increased BBB permeability is a critical contributor to HIV
neuropathogenesis as disruption of this regulatory interface facilitates CNS infiltration of
potentially harmful substances from the periphery, resulting in compounding viral entry
and susceptibility to the inflammatory assault of immune cells88. Gisslén and colleagues
demonstrated a significant relationship between QAlb, CSF HIV-1 RNA, and the
macrophage activation marker neopterin, thus suggesting a strong association between
immune activation as an important factor in BBB permeability in HIV infection87. In line
with this theory, monocyte infiltration has previously been found to correlate with loss of
tight junction immunoreactivity in brain tissue of HAD patients94. Similar to the
speculated mechanisms of neuropathogenesis outlined previously (See
"Neuropathogenesis in HAND" above), growing evidence suggests BBB permeability is
the result of a multifactorial process involving immune-mediated mechanisms, as well as
viral mechanisms. For example, the HIV-1 derived proteins Tat and gp120 exhibit direct
neurotoxic effects, but also severely compromise the integrity of the BBB, permitting the
entry of peripheral cytokines and additional infected monocytes and free virions 20.
Furthermore, infection of pericytes, which encircle and stabilize endothelial cells of the
BBB, has been shown to diminish tight junction integrity and increase permeability in
vitro93. Even in the presence of low HIV infection, astrocytes undergo altered end feet
signaling, accelerating endothelial apoptosis95. The inflammatory cascade that results
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from entry of peripheral cytokines and immune cells, further exacerbated by activation of
residential CNS macrophages and microglial cells, results in a storm of reactive oxygen
species, nitric oxide, glutamate, cytokines, and other neurotoxins that ultimately lead to
neuronal damage and death20. Interestingly, it should be noted that albumin itself
produces concentration-dependent neurotoxic effects in rat brain parenchyma in vivo96,
and induces expression of the pro-inflammmatory cytokines IL-1β and TNF-α possibly
via MAP-K activation in astrocytes and microglial cells97-99. Thus, it may be these
resident immune cells rather than infiltrating macrophages are the cause of neuroinflammation and neuro-toxicity once the BBB is compromised.
Although BBB dysregulation is thought to be secondary to viral and immunemediated processes directly related to HIV-infection, one must not discount the influence
of HIV-related comorbidities. Concurrent infections may significantly alter BBB, either
via direct NVU infection or induction of cytokines which indirectly cause BBB hyperpermeability. Most notably, up to one third of HIV-infected patients are concurrently
infected with Hepatitis C, which directly infects NVU endothelial cells and may cause
neurocognitive dysfunction37. Drug abuse is highly prevalent in HIV+ populations, with
cocaine and methamphetamine implicated in BBB dysruption38. Cardiovascular disease is
also commonly accelerated in HIV+ patients due to chronic systemic inflammation and
metabolic side effects of cART therapy (ie, protease inhibitors)35,100,101. Given the
presence of cardiovascular disease and its risk factors (hypertension,
hypercholesterolemia) have been associated with neurocognitive decline in HIV36, it
likely contributes to BBB hyper-permeability.
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III. Blood brain barrier status in early HIV infection
As indicated above, dysregulation of the BBB is a well-established event in chronic HIV
infection and correlates with neurological injury and neuro-inflammation. However there
is very limited data assessing blood brain barrier integrity during the primary phase of
infection. Moderate elevations of albumin ratio in PHI have previously been shown in
cross-sectional studies 50,60, and there exists a strong association between matrix
metalloproteinases--enzymatic surrogate markers of BBB permeability--and
neurocognitive status in early HIV102. Although studies assessing BBB status in PHI
patients are limited, several studies have analyzed albumin ratio in neuro-asymptomatic
patients (recruited regardless of chronicity/transmission date), often with mixed results,
either demonstrating increased QAlb compared to uninfected controls60,87 or no significant
difference32,103.

Role of cART therapy
I. cART therapy overview
Since clinical trials with azidothymidine (AZT) in 1987, it has been known that
antiretroviral therapy can significantly reverse HAD, as assessed by clinical
neuropsychological testing and positron emission tomography104. This improvement is
clearly enhanced with highly antiretroviral therapy (HAART)/combination ART
(cART)10,105, the standard of treatment for HIV. There are 24 FDA-approved ARTs
currently available with varying molecular actions: (1) nucleoside-analog reverse
transcriptase inhibitors (NRTIs), (2) non-nucleoside reverse transcriptase inhibitors
(NNRTIs), (3) protease inhibitors (PI), (4) integrase inhibitors, (5) fusion inhibitors, and
(6) co-receptor antagonists. Drugs from at least two different molecular classes are
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combined in a cART regimen (consisting of three or more drugs), with the underlying
purpose of preventing drug resistance106. Most commonly, regimens consist of two
NRTIs with one PI or one NNRTI. Nevertheless, cART regimens are highly
heterogeneous and may require complex, specific regimens necessitating as many as 30
pills a day17, though many patients are able to take single pill regimens in the modern era.
While certain regimens have a higher 'CNS Penetration Effectiveness' (CPE)107,
and thus better ability to cross the BBB and control CSF viral load, studies regarding the
clinical impact of CPE have been mixed52, primarily demonstrating unchanged or
worsened neuropsychological performance associated with these regimens108,109. Apart
from inherent bias involved in these study designs (ie, patients with more severe HAD
are prescribed a higher CPE regimen)34, there are other possible explanations. Not only
are high CPE drugs intuitively more likely to be neurotoxic, but some researchers argue
that the pathology of HAND is inflammation-mediated and not viral load-dependent (see
above sections), as the viral load may simply reflect plasma spillover from a leaky
BBB110. As cART medications directly target viral load and not the activated
inflammatory cascade, neuropsychological damage may persist with the continued lowgrade inflammation. Thus, as no specific cART regimen is considered superior for the
treatment of HAND16, individual regimens are based on the consideration of several
factors (ie, regimen complexity and compliance, CPE, drug-resistance testing).

II. Effects of cART therapy on neuropathogenesis in early infection
Given the remarkable and indisputable effect of cART on HAD, more recent studies have
aimed to assess cognitive benefits from earlier initiation of cART. In a longitudinal
observational study of PHI patients, cART therapy was shown to attenuate, although not
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fully reverse, abnormalities in MRS metabolite markers69. Although it was speculated
that normalization may occur beyond the limited follow-up period (median of 6.0
months), persistent neuroinflammation is known to occur despite successful cART (see
"Theories underlying persistence of HAND despite successful cART" above). Of note,
MRS markers of excitotoxicity exhibited greater attenuation than markers of
inflammation, perhaps suggesting persistent low-grade inflammation without significant
neurotoxicity. A similarly designed study assessed MRS abnormalities, but this time in
acute HIV infection (recruited within one month of transmission versus one year in PHI),
and found normalization with cART therapy70; thus, it may be that reversibility is
achieved with earlier cART initiation. Effects of cART on neuropsychological
performance in early infection have also been examined, although limited to two
studies71,72. The PHI study identified mild deficits with at least a partial response to
cART therapy; the second study, this time in acute HIV infection, demonstrated no
measurable neurocognitive deficits in the majority of patients, although a subgroup with
severe deficits showed very limited response to cART. The above studies suggest that
neuropathogenesis may have varied response to cART, as dictated by a combination of
factors, including timing of cART initiation and the severity of neurologic disease.

III. Effect of cART therapy on the blood brain barrier
Surprisingly, the effect of cART therapy on BBB permeability has not been intensely
evaluated. In an unpublished study, Crozier and colleagues reported the gradual
diminishment of albumin ratio from a median baseline of 6.48 to a median endpoint value
of 6.09 in 16 neuroasymptomatic patients with chronic HIV infection after 200 days of
cART therapy111; thus, although BBB integrity improved over time with cART therapy, a
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return to premorbid or near premorbid function may take years. In contrast, Abdulle and
colleagues observed no significant reduction in BBB permeability after 2 years of cART
treatment in 38 neuroasymptomatic patients32. Importantly, the median baseline albumin
ratio of patients in the Crozier study was higher (6.48, range: 4.79-10.29,) than that of
patients in the Abdulle study (4.45, range: 1.77-9.84), potentially contributing to the
discrepancy in cohort response to cART. No studies have investigated the effect of cART
therapy on BBB permeability in early stages of infection.

STATEMENT OF PURPOSE
In this study, we aimed to elucidate the natural history of BBB permeability during PHI,
and to determine whether these changes, if any, were associated with biomarkers of
neuropathogenesis. Additionally, we sought to determine whether BBB permeability was
responsive to cART treatment initiated during early HIV infection. Our specific study
questions and accompanying aims are delineated below:
I.

What is the natural history of blood brain barrier permeability during primary
HIV infection?
•

Aim: To determine the longitudinal trajectory of blood brain barrier
permeability, as measured by QAlb, in primary HIV infection, in the
absence of cART treatment.

II.

Is blood brain barrier status associated with neuropathogenesis during primary
infection?

17
•

Aim: To determine whether QAlb correlates with markers of neuronal
injury (NFL), neuronal health (NAA:Cr), and neuropsychological testing
(NPZ).

III.

Does early combination antiretroviral treatment (cART) influence QAlb?
•

Aim: To determine whether cART initiation effects the slope of the
QAlb trajectory established in Aim I, and associated markers of
neuropathogenesis in Aim II.

We hypothesized that a) QAlb will increase over time for cART-naive patients, and
b) QAlb will correlate positively with markers for neuronal injury (NFL), and inversely
with neuropsychological test performance (NPZ) and neuronal health (NAA:Cr).
Furthermore, c) following initiation of effective cART regimen, as indicated by reduced
CSF HIV-1 RNA, we expect QAlb to gradually diminish with improvement in
aforementioned markers of early CNS injury/inflammation.
These results will provide novel understanding of the changes to the brain
microenvironment that begin during initial HIV infection, and the persistence of these
alterations in the setting of early, virologically suppressive cART.

METHODS
Study design
Individuals with PHI were recruited into prospective longitudinal studies of CNS HIV in
Gothenburg, Sweden, and San Francisco, USA, between 1986 and 2014, as previously
described 60 and outlined below. Participants were within the first year of HIV
transmission as confirmed by the standard serologic testing algorithm for recent HIV
seroconversion (STAHRS) 112, and all but three were ART-naive. A subset began cART
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at variable times during follow up for reasons outside of the study. None of the
participants had a prior neurological disease history. A history of substance abuse was not
an exclusion criterion, but no participants reported same-day substance abuse, which
would have led to censoring of data. Date of HIV transmission was approximated as 14
days prior to the onset of seroconversion symptoms, when present 113; otherwise, it was
approximated as midway between the dates of the last negative and first positive EIA
test114. HIV-uninfected volunteers were recruited from the San Francisco community,
and had no history of neurological conditions nor active systemic diseases.

Ethics
The study protocol was approved by the institutional review board of each institution
involved. All study participants gave written consent.

Data collection and laboratory analysis
Paired CSF and blood/plasma samples were obtained and neuropsychological testing and
MRS were performed at each visit as described in detail below42,68. Study intervals were
scheduled at baseline (t=0), six weeks, and every six months thereafter, although there
was participant variation in timing and duration of follow up.

Following phlebotomy and lumbar puncture, CSF total WBC, lymphocyte counts, total
protein, albumin, and blood/plasma albumin were measured from fresh samples. Frozen
samples were prepared for assays of HIV RNA, neopterin, and NFL: Fresh samples were
maintained on ice, and, after low-speed centrifugation, cell-free CSF and paired blood
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plasma aliquots were stored within 2 hours of collection in −70°C to −80°C freezers.
Previous studies have demonstrated neopterin and NFL to tolerate repeated freeze-thaw
cycles and long-term storage with minimal compromise in integrity115,116, although both
conditions were minimized as much as possible throughout the course of this study.

CSF NFL was measured with the NF-light® ELISA kit (UmanDiagnostics AB, Umeå,
Sweden), a sensitive immunoassay with a lower limit of detection of 50 ng/L 86, and
reference values for upper limit of normal of 380 ng/L (18–29 years), 560 (30–39years),
890 (40–59 years), and 1850 (>59 years)86. CSF NFL assays were singularly performed
in the Laboratory of Neurochemistry at the University of Gothenburg on previously
frozen samples.

CSF and plasma albumin were measured by nephelometry (Behring Nephelometer
Analyzer, Behringwerke AG, Marburg, Germany). QAlb was calculated as the
CSF/plasma albumin ratio: CSF albumin (mg/l)/plasma albumin (g/l) 87. Upper limits of
normal were based on previously established values of <6.8 for age <45 years, and <10.2
for age >45 years 117. CSF and plasma albumin were measured in local clinical
laboratories. Given the inherent advantage of being a ratio, QAlb is laboratory- and
method-independent.

CSF and plasma neopterin was measured in the laboratory of Dr. Fuchs by commercial
immunoassays (BRAHMS, Berlin, Germany) on previously frozen samples. CSF white
blood cells, lymphocytes, total protein, and HIV RNA were measured in local
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laboratories as previously described60 and outlined below. CD4+ and CD8+ lymphocytes
and white blood cells were measured in fresh, paired CSF and blood/plasma samples
using flow cytometry. HIV RNA (viral load) was quantified in previously frozen, paired
cell-free CSF and plasma samples at local laboratories using either the ultrasensitive
Amplicor HIV Monitor PCR (version 1.5; Roche Molecular Diagnostic Systems,
Branchburg, NJ), Cobas TaqMan RealTime HIV-1 PCR (version 1 or 2; Hoffmann-La
Roche, Basel, Switzerland), or the Abbott RealTime HIV-1 PCR assay (Abbot
Laboratories, Abbot Park, IL, USA). Viral loads below 50 copies/mL were assigned a
value of 49 copies/mL (1.69 on log10 scale).

Neuropsychological performance was determined through the appraisal of gross and fine
motor skills, processing speed, executive function, learning, and verbal memory through
a battery of 11 tests. Performance was summarized as an aggregate total Z score and a
brief NPZ-4 score (including grooved pegboard, digit symbol, finger tapping, and timed
gait).

A trained neuro-radiologist interpreted MRI data for exclusion of non-HIV associated
pathologies and assignment of atrophy and white matter hyperintensity ratings. Brain
MRI/MRS was obtained at the San Francisco site only. MRS data were processed and
analyzed with the spectral fitting software SITools, which uses a parametric model of
known (metabolites) and modeled spectral components (macromolecules) to fit all
resonances and nonparametric parameters to the baseline. Metabolite disturbances can
indicate neuropathology, including inflammation and injury. The ratio of the peak area
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under the curve for the metabolite N-acetylaspartate to the peak area under the curve for
creatine-containing metabolites (NAA:Cr) is a putative marker of neuronal viability and
number. We focused spectral acquisition on the parietal grey matter, as we have
previously identified metabolite abnormalities in this region during PHI 68,69.

Statistical analysis
Baseline characteristics were summarized as frequencies for categorical variables and
median and IQR for continuous variables. Non-parametric, Chi-square, and Fisher's exact
test were used for group comparisons. Specifically, comparison between independent
groups was performed with the nonparametric method of Mann Whitney U-test for
continuous variables, unpaired t-test for normal distribution, and the chi2 test or Fisher's
exact test for categorical variables; comparison between dependent samples (repeated
measures of participants pre- and post-cART) was performed with Wilcoxon signed-rank
test. Analysis of covariance (ANCOVA) was performed to compare QAlb between PHI
and controls while adjusting for the potential confounders of age and sex.

The mixed-effects model was used to analyze longitudinal change of QAlb posttransmission, both pre- and post-cART. This model includes both fixed and random
effects in the same analysis, allowing for variation in the number and time interval of
participant follow-up visits. Because albumin ratio increases with normal aging, the
equation was adjusted for baseline age by including it as a fixed-effect covariate in the
model. To account for a possible non-linear trajectory of QAlb over time, a quadratic term
(t2) was also included as a fixed-effect covariate along with days post-transmission (t).
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The model included a personal intercept for each subject as a random effect, allowing
baseline QAlb to vary for each participant. An interaction term was initially added to
assess whether the trajectory of QAlb over time depended on the baseline QAlb, but was
found to be insignificant and thus excluded from the final model. QAlb values were logtransformed for normal distribution before longitudinal analysis. As transformed results
were comparable to non-log-transformed analysis, the latter results are reported for
familiarity of QAlb values. For the equations generated, the final y-intercept was
calculated as follows: [(parameter estimate of baseline age)*(median age of
subgroup)]+parameter estimate of subgroup intercept.

Partial correlation coefficients were calculated to determine potential relationships
between QAlb and other measured parameters, as indicated, while adjusting for effects of
age. Correlations were computed as a cross-sectional analysis using each participant's
baseline values, as well as a longitudinal analysis using the intra- and inter-subject
method of Bland and Altman118,119. Specifically, the intra-subject, or 'within subject',
method determines the correlation of QAlb and a second variable within a subject over the
course of the study, thus assessing the longitudinal relationship between the two variables
while removing variation due to subjects. In other words, it assesses whether an increase
in the QAlb of an individual subject is associated with a change in the second variable. For
the inter-subject, or 'between subject', method, each subject's repeated measures over the
course of the study are averaged for QAlb and the second variable, and a simple regression
is performed with the weighted means. In other words, this approach assesses whether
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individuals with elevated QAlb throughout the study also tended to have
elevated/depressed values of the second variable.

Statistical analyses employed SPSS 23.0 statistical package (IBM Corp., Armonk, NY).
Significance level was set as p<0.05, two-sided.

Author contributions
Patient recruitment, data collection, and laboratory analysis were performed previously
by the research groups of Drs. Serena Spudich, Magnus Gisslén, and Richard W. Price in
their cohort studies evaluating the CNS effects of HIV in PHI. This study of blood brain
permeability in the context of the data available from these cohorts was designed by
Elham Rahimy and Serena Spudich. Statistical analyses were performed by Elham
Rahimy and confirmed by Fang-Yong Li. Additionally, Fang-Yong Li provided
invaluable teaching on the more complex statistical analyses such as the mixed-effects
model. Elham Rahimy also created figures, tables, and drafted the manuscript. All the
authors assisted in revising the manuscript and approved the final version.

RESULTS
Study participant characteristics
106 PHI participants fulfilled the inclusion criteria and had available QAlb values. Nine
participants experienced clinically overt neurological disorders during seroconversion:
meningitis (n=2), headache with photophobia (n=5), brachial neuritis (n=2), GuillainBarre syndrome, facial palsy, and encephalitis. Total visits ranged from 1 to 13 with a
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median of 2, and follow-up ranged up to 3572 days with a median of 50 days. The
majority of participants were infected with subtype B virus 60.

The baseline characteristics of PHI and uninfected control participants are presented in
Table 1. The median duration of HIV infection in PHI participants was 91 days; plasma
viral load in PHI was 1.8 log10 greater relative to that in the CSF compartment. As
compared to the HIV-uninfected participants, the PHI cohort had a higher percentage of
males, and was younger. As expected, PHI participants had a lower CD4 count, elevated
CD8 count, and decreased CD4/CD8 ratio. As previously reported, CSF white blood cells
were elevated in the PHI group, as well as CSF neopterin, a marker of macrophage
activation. Despite the younger age, PHI participants had elevated NFL and equivalent
CSF total protein compared to the uninfected group, two parameters that increase with
normal aging 86,120,121.

Information regarding drug and alcohol use was available for participants from the San
Francisco site (n=82) only: 33.0% reported recent alcohol abuse, and 49.1% reported
recent drug use. The most frequently reported drug use were methamphetamine,
marijuana, and cocaine, in descending order.

25
Table 1. Baseline demographic and clinical characteristics of study participants
Primary HIV infection
(n=106)

HIV uninfected
(n=64)

p value

94!

82!

0.001!

Age (y)

36 (29, 46)!

43 (34, 50)!

0.003!

Site

SF!(n=82)!!
GOT!(n=24)!

SF!

Days post-HIV transmission

91 (53, 149)!

---!

---!

CD4+ count (cells/µl)

567 (402, 709)

808 (678, 1009)

<0.001

CD8+ count (cells/µl)

954 (714, 1358)

487 (343, 733)

<0.001

0.528 (0.391, 0.791)

1.76 (1.32, 2.18)

<0.001

Plasma HIV RNA (log10copies/ml)

4.69 (4.08, 5.34)

---

---

CSF HIV RNA (log10copies/ml)

2.83 (2.14, 3.51)

---

---

Plasma:CSF HIV RNA ratio
(log10copies/ml)

1.81 (1.33, 2.28)

--

--

CSF WBC count (cells/mm3)

6 (2, 11)

2 (0, 3)

<0.001

41 (31, 51)

41 (31, 54)

0.611

NFL (pg/ml)

518 (391, 819)

411 (320, 550)

<0.001

CSF neopterin (nmol/l)

9.6 (6.8, 20.4)

5.0 (4.1, 6.8)

<0.001

8.5% (n=9)

--

--

2 (1, 3)

---

---

50 (0, 450)

---

---

Sex (% male)

CD4/CD8

CSF total protein (mg/dl)

% neurosymptomatic ARS
Total number of visits
Duration of follow up (days)

Values are expressed as median and IQR (Q1, Q3).
ARS, acute retroviral syndrome; CSF, cerebrospinal fluid; GOT, Gothenburg, Sweden; NFL, neurofilament
light chain; SF, San Francisco, USA; WBC, white blood cell count.

Blood brain barrier permeability at baseline
At baseline, age adjusted QAlb was elevated in the PHI cohort compared to controls
(means 5.9, 95% CI 5.5 to 6.3 in PHI; and 5.0, 95% CI 4.4 to 5.6 in controls; p=0.02).
Using previously published reference values117, baseline QAlb was above the age-specific
upper limit of normal (ULN) in 22 PHI participants (21%), referred to as the "high
baseline QAlb subgroup." The remaining 84 PHI participants with baseline QAlb values
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below the ULN are referred to as the "normal baseline QAlb subgroup." The baseline
clinical characteristics of these two subgroups are summarized in Table 2. 4/17, or 24%,
in the high baseline QAlb subgroup had neurosymptomatic seroconversion versus 8/64, or
13%, in the normal baseline QAlb subgroup, although statistically insignificant. Elevated
NFL, CSF total protein, CSF neopterin (but not blood neopterin), CD8+ T cell count, and
a decreased plasma:CSF HIV RNA ratio were found in the high baseline QAlb as
compared to normal baseline QAlb group.
Table 2: Baseline clinical characteristics of high and normal QAlb subgroups
Subgroup with
High Baseline QAlb
(n=22)

Subgroup with
Normal Baseline QAlb
(n=84)

p value

Age (y)

36 (29, 45)!

37 (28, 46)!

0.797!

Days post-HIV transmission

85 (60, 125)!

92 (51, 150)!

0.785!

CD4+ count (cells/µl)

596 (484, 681)

550 (389, 730)

0.469

CD8+ count (cells/µl)

1294 (792, 1620)

915 (706, 1200)

0.023

0.463 (0.321, 0.791)

0.530 (0.391, 0.803)

0.376

Plasma HIV RNA (log10copies/ml)

4.60 (3.91, 5.39)

4.69 (4.09, 5.32)

0.629

CSF HIV RNA (log10copies/ml)

3.23 (1.77, 3.87)

2.73 (2.14, 3.43)

0.340

Plasma:CSF HIV RNA ratio
(log10copies/ml)

1.27 (0.464, 2.16)

1.84 (1.50, 2.29)

0.020

CSF WBC count (cells/mm3)

7 (4, 13)

5 (2, 11)

0.087

59 (52, 74)

37 (28, 42)

<0.001

NFL (pg/ml)

857 (468, 1474)

498 (360, 729)

0.008

Blood neopterin (nmol/l)

18.0 (10.8, 28.9)

14 (9.4, 21.3)

0.183

CSF neopterin (nmol/l)

14.3 (8.4, 32.0)

9.0 (6.5, 17.4)

0.035

Baseline QAlb

9.18 (7.5, 11.3)

4.66 (3.57, 5.75)

<0.001

18% (n=4)

6.0% (n=5)

---

2 (1, 3)

2 (1,3)

0.617

48 (0, 398)

51 (0, 455)

0.715

CD4/CD8

CSF total protein (mg/dl)

% neurosymptomatic ARS
Total number of visits
Duration of follow up (days)

Values are expressed as median and IQR (Q1, Q3).
ARS, acute retroviral syndrome; CSF, cerebrospinal fluid; NFL, neurofilament light chain; WBC, white
blood cell count.
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Statistically significant parameters are bolded.

Longitudinal blood brain barrier permeability in PHI prior to cART
The individual trajectories of each PHI participant's QAlb over the duration of the study
prior to cART initiation are plotted in Figure 2. A mixed model analysis to evaluate the
natural history of blood brain barrier integrity in the overall PHI group prior to cART did
not reveal a significant change in QAlb over time (-0.000436/day, p=0.092). Figure 3
compares the trajectories of the high and normal baseline QAlb groups. The high baseline
group showed a declining trend (-0.00305/day, p=0.011) while the normal baseline group
initially increased (0.00144/day, p= 0.006) and reached a plateau quickly (quadratic time
effect p= 0.004). These results indicated the heterogeneous time effect in two subgroups.

Figure 2: Natural history of blood brain barrier integrity pre-cART in total cohort.
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Figure 3: Natural history of blood brain barrier integrity pre-cART upon cohort stratification. Graphs
demonstrate individual participant and overall trajectory of QAlb in cART-naive participants upon
stratification into high and low baseline QAlb subgroups. Dashed gray lines simply indicate upper limit of
normal for participants aged <45 years (at QAlb=6.5) and those aged >45 years (at QAlb=10.2).

Correlation of blood brain barrier integrity with markers of neuropathogenesis
To further evaluate the implications of elevated QAlb, correlations between QAlb and
markers of neuronal health were evaluated in pre-cART study intervals (Figure 4).
Partial correlation coefficients were calculated to correct for the confounding effects of
age, as QAlb and NFL both directly correlate with age. QAlb demonstrated a strong positive
correlation with NFL, a marker of active neuronal injury, upon cross-sectional analysis at
baseline (r=0.497, p<0.001), and longitudinally with both between-participant (r=0.555,
p<0.001) and within-participant analysis (r=0.523, p=0.001). QAlb inversely correlated
with NAA:Cr, a cerebral metabolite biomarker of neuronal health, upon cross-sectional
analysis at baseline (r=-0.352, p=0.015), and longitudinally with between-participant
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analysis (r=-0.387, p=0.008) but not within-participant analysis (r=0.218, p=0.125). MRS
was performed at a median 114 days post infection (dpi). QAlb did not correlate with
composite z-scores (total Z or NPZ4) of neuropsychological testing at baseline nor in
longitudinal analysis (data not shown).

Figure 4: Correlation of blood brain barrier permeability with clinical and laboratory indicators of
neuropathogenesis.
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Characteristics of cART-treated study participants
Fifty-eight PHI participants initiated a cART regimen during study follow-up, although
one participant was excluded for virologic failure (two consecutive plasma samples with
HIV RNA >50 copies/mL after 6 months of ART). Treatment regimens were
heterogeneous, consisting of 10 integrase-based, 25 protease-based, and 22 NNRTI-based
(15 of which were efavirenz-based), with 19 distinct combinations. cART was initiated at
a median 225 dpi, with 402 days median on-cART follow-up. Table 3 compares the
cross-sectional laboratory parameters before (last visit before treatment) and after cART
treatment (last visit of study) in those who initiated cART. There was improvement in
most parameters after approximately a year of cART: suppression of plasma and CSF
HIV RNA to the lower limit of PCR detection (p<0.001), increased CD4+ counts
(p<0.001), decreased WBC count (p<0.001), and decreased blood and CSF neopterin
(p<0.001). In this comparison, NFL and albumin ratio did not significantly change with
cART treatment (640 vs 670, p=0.911; 5.18 vs 5.09, p=0.851).
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Table 3: Pre- and post-treatment characteristics of participants initiating cART
!

Last pre-cART visit (n=57)!

cART-treated endpoint!

p value!

41 (29, 46)

---

---

Days post-HIV transmission

225 (96, 760)

---

---

Days prior to ART initiation

19 (3, 85)

---

---

# follow-up visits

---

2 (1, 6)

---

Days on cART

---

402 (192, 1060)

---

431 (282, 588)

643 (483, 787)

<0.001

Plasma HIV RNA (log10copies/ml)

4.9 (4.4, 5.3)

1.69 (1.69, 1.69)

<0.001

CSF HIV RNA (log10copies/ml)

3.4 (2.6, 4.0)

1.69 (1.69, 1.69)

<0.001

1.49 (0.71, 2.08)

0.00 (0.00, 0.20)

<0.001

Age (y)

CD4+ count (cells/µl)

Plasma:CSF HIV RNA ratio
(log10copies/ml)
CSF WBC count (cells/mm3)

4 (6, 14)

2 (1, 3)

<0.001

40 (33, 50)

35 (29, 42)

0.001

640 (515, 965)

670 (453, 1072)

0.911

QAlb

5.18 (3.92, 6.40)

5.09 (3.87, 6.21)

0.832

Blood neopterin (nmol/l)

18.4 (8.4, 24.9)

7.6 (5.2, 12.9)

<0.001

CSF neopterin (nmol/l)

13.9 (7.8, 21.6)

5.2 (4.7, 7.7)

<0.001

CSF total proteinA
NFL (pg/ml)B

Values are expressed as median and IQR (Q1, Q3). Group comparisons were performed using nonparametric analysis for related samples.
CSF, cerebrospinal fluid; NFL, neurofilament light chain; WBC, white blood cell count.
A
n=21 paired; Bn=42 paired.
Statistically significant parameters are bolded.

Longitudinal history of blood brain barrier integrity following cART initiation
A mixed model analysis was performed to assess the longitudinal trajectory of QAlb over
13 months of cART (Figure 5). Three participants were recruited into the cohort already
on cART (for 29, 27, and 19 days) and thus were included in the linear mixed model
(n=60) but excluded from Table 3. As cART was initiated at a median of 225 dpi (t=0 on
Figure 5), this time-point corresponded with the linear portion of Figure 3, where the
quadratic changes of the normal baseline subgroup are resolving and reaching a set-point.
Thus, initial analysis was performed with the total cART-treated group rather than
separating into subgroups of high and normal baseline QAlb. There was no significant
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change detected in QAlb over the median >1 year duration of cART treatment (slope=0.00369/month, p=0.174). With group stratification, the high baseline subgroup (n=7)
demonstrated no significant change in QAlb over time (p=0.783). The low baseline
subgroup (n=53) demonstrated a slope of effectively zero (slope=0.00008/month,
p=0.004), similar to the pre-cART plateau.

Figure 5: Effects of cART on trajectory of blood brain barrier permeability. Scatterplot shows individual
participant and overall trajectory of QAlb pre- and post- cART initiation (indicated by dashed red line at
t=0). Linear mixed model analysis generated the equations shown. Blue line shows trajectory of QAlb precART initation and red line shows trajectory of QAlb post-cART initiation. Months pre-cART are negative
values.

DISCUSSION
In this study, we analyzed the natural history of BBB permeability during primary HIV
infection, and the influence of early cART. We showed that the albumin ratio is mildly
elevated in PHI participants compared to uninfected controls when correcting for age.
This correction is relevant given that BBB permeability increases with normal aging122,
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and may explain why previous studies have not reported abnormalities in BBB
permeability during PHI when compared to controls, given that most early HIV studies
enroll young patients. That being said, we have previously identified moderate elevation
of albumin ratio in PHI 50,60, and in chronic HIV participants who are cART-naive and
neuroasymptomatic60. Similarly, Li et al have reported a strong association between
matrix metalloproteinases--enzymatic surrogate markers of BBB permeability--and
neurocognitive status in early HIV102.
The novelty of this study is our finding that BBB permeability is undergoing
dynamic changes early in the course of HIV infection, even within days of transmission.
Two distinct trajectories were noted for the PHI cohort when stratified by baseline
albumin ratio. Those with a normal baseline albumin ratio (below the ULN) showed a
mild initial increase that plateaued within the first 1000 days of infection. Despite the
initial rise, the QAlb remains well below the ULN. As will be discussed below, it may be
that there is an element of sub-clinical injury associated with this mild rise. The
subgroup with high baseline albumin ratios demonstrated a marked decline in albumin
ratio within the first 1000 days of infection. Presumably an early rise in albumin ratio
occurred immediately following infection before participant recruitment, and is resolving
during the follow up. Notably, the subgroup with higher baseline albumin ratio was
characterized by a higher percentage of neurosymptomatic seroconversion, elevations in
CSF markers of axonal injury and immune activation, and a higher CSF-to-plasma HIV
RNA ratio. These findings suggest that a subgroup of PHI participants is susceptible to
marked BBB disruption, which persists even beyond 1000 days post infection, and is
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associated with signs of increased CNS involvement. Factors which predispose
individuals to one trajectory versus the other warrant further investigation.
Previous studies have expounded on the association of albumin ratio with
biomarkers of CNS inflammation and injury123. We confirm that in PHI albumin ratio
correlates strongly with the axonal injury marker NFL68, and newly demonstrate that it
inversely correlates with the metabolic marker of neuronal health, NAA:Cr. NFL is a
sensitive marker of active neuronal damage, and its levels correlate with the severity of
this damage 51,124,125. We have previously shown NFL to be the most sensitive neuronal
biomarker for assessing HIV neurodegeneration, as it can detect subclinical injury in
neuroasymptomatic individuals, even in the early phase of infection 50,126. As disease
progresses, it is also associated with overt clinical neurological disease, thus not only
reflecting structural but functional changes124. Although NFL is not specific for HIV
neurodegeneration50,51, comorbid neurological conditions were excluded from the study
onset. Similar to QAlb, NFL was elevated in PHI although below the ULN (<560),
possibly indicating subclinical damage, which may explain the lack of correlation with
NPZ-4 testing. In line with this conclusion, we have previously shown a lack of
correlation between NFL and NPZ-4 during PHI, despite showing moderate elevations
when compared to uninfected controls 50,68. Similar to the utility of NFL as a biomarker
of early subclinical injury, MRS has been shown to detect early HIV neuropathogenesis
prior to conventional MRI changes127. In a recent study, chronically infected HIV
subjects with cognitive defects were shown to have reduced glutamate and NAA in
several brain regions, most pronounced in the parietal grey matter128. Here, we extend
that finding to the early stage of infection.
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Once we demonstrated that BBB permeability was altered in PHI, and associated
with markers of neuronal pathology, we assessed whether early cART treatment could
remediate these changes. Surprisingly, the effect of cART on BBB permeability has not
been intensely evaluated. In an unpublished study, Crozier and colleagues observed the
gradual diminishment of albumin ratio (median 6.48 to 6.09) in 16 neuroasymptomatic
participants with chronic HIV infection after 200 days of cART therapy111; thus, although
BBB integrity improved over time with cART therapy, a return to baseline or near
baseline function may take years. In contrast, Abdulle and colleagues reported no
significant reduction in BBB permeability after 2 years of cART treatment in 38
neuroasymptomatic participants32. Importantly, the median baseline albumin ratio of
participants in the Crozier study was greater than that of participants in the Abdulle study
(6.48 vs 4.45), potentially contributing to the discrepancy in cohort response to cART.
In our study, cART treatment, initiated at a median of 225 days post infection,
was effective in suppressing CSF and plasma HIV RNA, suggesting medication
compliance and effectiveness. Notably, the inflammatory marker neopterin improved to
below the upper level of normal limits both in the plasma and CSF. Despite this systemic
(including CNS) suppression of viral replication and inflammation, NFL and albumin
ratio were unchanged. The pre-cART measurement of albumin ratio is comparable to the
age-matched uninfected controls, and thus may indicate that the acute changes of albumin
ratio in the high baseline QAlb subgroup had largely resolved and reached near-baseline
once cART was initiated at 225 days post infection. On the other hand, although NFL is
below the age-specific ULN (<840), it is elevated compared to uninfected controls and
the baseline PHI cohort, given only a marginal age difference. There is a gradual
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normalization of NFL following axonal injury which is unlikely to persist for over a
year129. Thus, this persistently elevated level of NFL may reflect continued subclinical
injury despite cART treatment and what appears to be a largely normal albumin ratio.
Notably, we have previously shown a reduction in NFL in response to cART124.
However, there are important distinctions between the two studies. Although both cohorts
demonstrate approximately equal proportion of patients with elevated age-specific NFL
values (38% in the current study, 40% in the previous), the elevations are much less
marked in the current study: the patients in the current study demonstrate a lower baseline
NFL upon cART initiation (640 pg/mL [IQR 515, 965] vs 780 ng/L [IQR 480, 7300]) for
a slightly older cohort (median 41 vs 38 years). Additionally, the previous study had a
large proportion of neurologically symptomatic patients (ie, with ADC), whom were
noted to have the more marked elevations in NFL. Furthermore, the current study uses a
more sensitive NFL assay, possibly more accurately detecting subtle elevations in NFL
that remain persistently elevated after cART. Our findings in the current study are
consistent with a more recent study from the Gisslén/Zetterberg group using the same
highly sensitive assay86 that demonstrated that the subgroup of HIV-infected individuals
with normal CSF NFL at baseline exhibited no significant reduction in CSF NFL after
treatment initiation, and also that in the overall group studied, NFL levels did not
completely normalize in the setting of long-term cART. Finally, the current study is
assessing early stage primary HIV infection, while the previous study was assessing
chronic HIV infection/AIDS, thus there may be inherent differences between the two
disease stages (although beyond the scope of this study).
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We hypothesize that perhaps (1) the initially altered BBB permeability has
initiated CNS injury which persists despite resolution of BBB integrity, (2) the
mechanism of injury is independent of BBB integrity, or (3) BBB permeability is mildly
elevated and has not fully returned to baseline resulting in persisting neuronal injury.
Alternatively, it is possible that despite the large sample size, we still have insufficient
power to detect a significant change in NFL and QAlb after cART. Further studies are
necessary to elucidate the possible explanation. Notably, a previous study showed
normalization of the CD4/CD8 ratio during PHI only when cART was initiated within 6
months of transmission130. Furthermore, in a cohort of individuals started on treatment
during acute HIV, CSF NFL was not elevated at baseline nor after 6 and 24 months of
cART131. The effects of earlier cART intervention on albumin ratio normalization should
be investigated.
Limitations
In light of the genetic diversity of HIV, the findings of this study are most representative
of infection with HIV-1 subtype B, the predominant form in Europe, Australia, and the
Americas132 and the subject of most in vitro experiments and antiretroviral drug
experiments133.
QAlb is affected by many factors not accounted for in this study, including body
weight and smoking 122. Comorbidities which are highly prevalent in HIV+ individuals,
such as cardiovascular disease and diabetes mellitus, are known to influence the integrity
of the BBB. In this study, cholesterol and other cardiovascular risk factors were not
routinely screened for, although none of the participants had a known history of clinically
apparent cardiovascular disease such as coronary artery disease, peripheral vascular
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disease, or stroke. One participant, in the low baseline group, had a known diagnosis of
diabetes mellitus type 2. Abuse of substances such as cocaine has been shown to at least
transiently increase BBB permeability45. As indicated in the results, drug use was highly
prevalent in this cohort, thus, misreporting of ongoing drug use or long-term effects of
previous drug use cannot be discounted as confounding factors.
Furthermore, given the observational nature of this study, cART regimens were
heterogeneous which may result in distinct effects on the BBB. The influence of distinct
regimens is further complicated by the fact that several participants changed cART
regimens throughout the course of the follow-up period for different reasons (ie, drug
reactions). Therefore, the sample size we have is too small to support a meaningful
comparison by therapy.
In light of the limitations delineated above, the ideal confirmatory study would
recruit healthy subjects without confounding factors of BBB status--HBV/HCV negative,
no previous history of drug or alcohol use, no history of cardiovascular disease or
cardiovascular risk factors, including hypertension, diabetes, or even obesity. Participants
would be recruited nationwide via different universities/institutions, and would include a
greater female population (large enough for further analysis upon sex stratification) and
larger age distribution (again, large enough for further analysis upon stratification).
Follow-up would begin from day 1 of HIV transmission and follow-up time would be
homogeneous for all participants (ie, at baseline, six weeks, and every six months
thereafter until the last day without any loss to follow-up). Participants would have
excellent access to health care throughout the observational study, so as to minimize
interference of confounding health conditions on the different measured CSF and blood
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parameters. A large portion of participants would then start an antiretroviral therapy
regimen within the PHI phase and remain compliant with successful viral suppression.
With an earlier cART initiation, we may thus be able to better assess the effect of cART
on the BBB permeability trajectory compared to the cART-naive population.
Additionally, if cART regimens were more homogeneous among participants, we may be
able to stratify based on regimen characteristics (ie, CPE) to determine if unique
regimens exhibit different effects on BBB permeability.

Conclusions
Blood brain barrier permeability undergoes a dynamic process early in HIV infection,
demonstrating acute changes within days. We identified two subgroups of PHI
participants with different albumin ratio trajectories: one with a presumed acute increase
and gradual improvement over the course of infection, and a second with a mild initial
increase. BBB permeability correlated with markers of neuropathogenesis. Initiation of
cART in the first year of infection did not significantly alter BBB permeability in our
study. Further investigations should test the effects of earlier cART initiation, especially
in individuals with signs of early BBB disruption.
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